IBO

Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.

Wall Street analysts forecast IBO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Impact Biomedical Inc revenue for the last quarter amounts to 18.00K USD, decreased % YoY.

Impact Biomedical Inc. EPS for the last quarter amounts to -0.12 USD, decreased -300.00 % YoY.

Impact Biomedical Inc (IBO) has 2 emplpoyees as of December 15 2025.

Today IBO has the market capitalization of 50.80M USD.